Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?

The combination of hypomethylating agents and histone deacetylase inhibitors demonstrates promising results in phase 1 trials but unfortunately disappointing results in all phase 2 trials to date. See also pages 000-000.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jGGyYb
via IFTTT